MétaCan
Menu
Back to cohort
Record W3028216699 · doi:10.1002/oby.22794

Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5

2020· article· en· W3028216699 on OpenAlexafffund
Robert F. Kushner, Salvatore Calanna, Melanie J. Davies, Dror Dicker, W. Timothy Garvey, Bryan Goldman, Ildiko Lingvay, Mette S. Thomsen, Thomas A. Wadden, Sean Wharton, John Wilding, Domenica Rubino

Bibliographic record

VenueObesity · 2020
Typearticle
Languageen
FieldMedicine
TopicDiabetes Treatment and Management
Canadian institutionsYork University
FundersNIHR Leicester Biomedical Research CentreMitsubishi Tanabe Pharma CorporationServierEisaiZafgenAstellas PharmaMylanMannKind CorporationBausch HealthUniversity of PennsylvaniaNovo NordiskNational Institute for Health and Care ResearchIntarcia TherapeuticsTeva Pharmaceutical IndustriesGilead SciencesSanofiNational Institute of Diabetes and Digestive and Kidney DiseasesAmgenPfizerAstraZenecaEli Lilly and CompanyBristol-Myers Squibb
KeywordsSemaglutideMedicineWaistPlaceboOverweightObesityType 2 diabetesTolerabilityWeight lossPopulationCircumferenceClinical trialPhysical therapyInternal medicineDiabetes mellitusAdverse effectAlternative medicineEndocrinologyLiraglutideEnvironmental health

Abstract

fetched live from OpenAlex

OBJECTIVE: The obesity epidemic is a public health concern, warranting further research into pharmacological treatments for weight management (WM) as an adjunct to lifestyle interventions. The Semaglutide Treatment Effect in People with obesity (STEP) program aims to investigate the effect of semaglutide versus placebo on weight loss, safety, and tolerability in adults with obesity or overweight. METHODS: Across five phase 3 trials (NCT03548935, WM; NCT03552757, WM in type 2 diabetes; NCT03611582, WM with intensive behavioral therapy; NCT03548987, sustained WM; and NCT03693430, long-term WM), ~5,000 participants are being randomly assigned to receive semaglutide 2.4 mg once weekly subcutaneously versus placebo. Results will be available in 2020/2021. For all trials, the primary end point is change from baseline to end of treatment in body weight. RESULTS: and a mean waist circumference of 113.0 to 115.7 cm. CONCLUSIONS: The STEP program evaluates the efficacy and safety of semaglutide 2.4 mg subcutaneously once weekly in a broad population. The trials will provide insights on WM in people with obesity with and without type 2 diabetes and on long-term follow-up.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.010
metaresearch head score (Gemma)0.008
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Not applicable · Consensus signal: none
GenreCandidate signal: Review · Consensus signal: none
Teacher disagreement score0.011
Threshold uncertainty score0.053

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.0100.008
Meta-epidemiology (narrow)0.0010.000
Meta-epidemiology (broad)0.0020.002
Bibliometrics0.0000.000
Science and technology studies0.0010.001
Scholarly communication0.0020.001
Open science0.0010.001
Research integrity0.0020.003
Insufficient payload (model declined to judge)0.0110.002

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.065
GPT teacher head0.312
Teacher spread0.248 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designNot applicable
Domainnot available
GenreReview

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations275
Published2020
Admission routes2
Has abstractyes

Explore more

Same venueObesitySame topicDiabetes Treatment and ManagementFrench-language works237,207